Immix Biopharma (IMMX) Return on Capital Employed (2022 - 2026)
Immix Biopharma (IMMX) posted Return on Capital Employed of 40.18% for Q1 2026, up 29.78% sequentially from 57.22% in Q4 2025, and up 13953.0% YoY from N/an in Q1 2025.
Immix Biopharma (IMMX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Immix Biopharma has reported Return on Capital Employed for 5 years, with the latest figure at 40.18% in Q1 2026.
- Quarterly Return on Capital Employed rose 13953.0% year-over-year to 40.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.18% (up 13953.0% YoY) and the FY2025 annual result came in at 55.7%, up 12215.0% from the prior year.
- Return on Capital Employed rose to 40.18% in Q1 2026 per IMMX's latest filing, from 57.22% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 13.44% in Q1 2022 and troughed at 343.22% in Q3 2025.
- A 5-year average of 107.14% and a median of 89.44% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 23380 bps in 2025, then surged 13953 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 55.24% in 2022, then tumbled by 67 bps to 92.35% in 2023, then plunged by 60 bps to 147.64% in 2024, then surged by 61 bps to 57.22% in 2025, then grew by 30 bps to 40.18% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 40.18%, 57.22%, and 343.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | -26.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.44% |
| Mar 31, 2026 | -40.18% |
| Dec 31, 2025 | -57.22% |
| Sep 30, 2025 | -343.22% |
| Jun 30, 2025 | -306.72% |
| Mar 31, 2025 | -179.71% |
| Dec 31, 2024 | -147.64% |
| Sep 30, 2024 | -112.92% |
| Jun 30, 2024 | -72.92% |
| Mar 31, 2024 | -89.44% |
| Dec 31, 2023 | -92.35% |
| Sep 30, 2023 | -89.90% |
| Jun 30, 2023 | -96.47% |
| Mar 31, 2023 | -74.76% |
| Dec 31, 2022 | -55.24% |
| Sep 30, 2022 | -28.55% |
| Jun 30, 2022 | -20.66% |
| Mar 31, 2022 | -13.44% |